# Clave Capital

> Clave Capital is a VC fund backing Biotechnology and Health Diagnostics. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Jardim Paulista, Brazil
- Total investments: 9
- Last investment: Oct 2025
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/clavecapital
- Website: https://www.clavecapital.com.br

Clave Capital is an independent asset management company that specializes in investment strategy.

## Contacts

5 contacts available for Clave Capital. Shizune tracks 1 team members at Clave Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/clave-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $653k–$7.3M |
| Venture - Series Unknown | $6.1M–$31M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 44% |
| Health Diagnostics | 3 | 33% |
| Health Care | 2 | 22% |
| Pharmaceutical | 2 | 22% |
| Mobile | 1 | 11% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 33% |
| Venture - Series Unknown | 2 | 22% |
| Series A | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 5 | 56% |
| Brazil | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Nader | Partner and Head of Real Estate | 0 | https://shizune.co/investors/profile/daniel-nader-2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nanoligent | Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively targetthe cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. | $14.1M | Series A | Oct 06, 2025 |  |
| Turbi | Turbi is a digital shared mobility company that makes car rental experience practical, cheaper and unique | $30.8M | Venture - Series Unknown | Jan 11, 2024 |  |
| MiMARK | MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $4.2M | Seed | Nov 27, 2023 |  |
| Nanological | Nanological is a public research organization, that focuses on pathogen identification devices. Nanological is a team of biosensing experts including physicists, biologists, data scientists, finance and business development experts, and clinical validation specialists. | $653.3K | Seed | Nov 22, 2023 |  |
| Nanological | Nanological is a public research organization, that focuses on pathogen identification devices. Nanological is a team of biosensing experts including physicists, biologists, data scientists, finance and business development experts, and clinical validation specialists. | $653.3K | Seed | Nov 22, 2023 |  |
| ADmit Therapeutics | ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer. | $6.1M | Venture - Series Unknown | Jul 19, 2023 |  |
| OneChain Immunotherapeutics | OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez. | $7.3M | Seed | Jun 22, 2023 |  |
| MiMARK | MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $1.1M | Seed | Jun 08, 2023 |  |
| MiMARK | MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $1.1M | Seed | Jun 08, 2023 |  |

9 of 9 investments shown.

## Co-investors
- [Nara Capital](https://shizune.co/investors/profile/nara-capital-6ad8) — VC Fund, 4 deals together
- [Namarel Ventures](https://shizune.co/investors/profile/namarel-ventures) — VC Fund, 3 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 2 deals together
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund, 2 deals together
- [WA4STEAM](https://shizune.co/investors/profile/wa4steam) — VC Fund, 2 deals together
- [ADDF's Diagnostics Accelerator](https://shizune.co/investors/profile/addf-s-diagnostics-accelerator) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Spain](https://shizune.co/investors/biotechnology-investors-spain)
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)
- [Biotech Investors in Spain](https://shizune.co/investors/biotech-investors-spain)
- [Biotech VC Funds in Spain](https://shizune.co/investors/biotech-vc-funds-spain)
- [Health Care Investors in Spain](https://shizune.co/investors/health-care-investors-spain)
- [Health Care VC Funds in Spain](https://shizune.co/investors/health-care-vc-funds-spain)

## FAQ

### What does Clave Capital invest in?

Clave Capital invests primarily in Biotechnology, Health Diagnostics and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 9 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Clave Capital's check size?

Clave Capital typically joins rounds of $653k–$7.3M at Seed and $6.1M–$31M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Clave Capital participates in.

### How do I contact Clave Capital?

Public channels for Clave Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Clave Capital?

The team at Clave Capital includes Daniel Nader (Partner and Head of Real Estate). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co